Ajanta Pharma gets US FDA approval for aripiprazole tabs

Aripiprazole tablets will be launched in the US soon

Ajanta Pharma has announced the receipt of final approval for aripiprazole tablets (2mg, 5mg, 10mg, 15mg, 20mg, 30mg), the bioequivalent generic to Abilify1 from the US FDA. Ajanta Pharma US, a wholly-owned subsidiary, will launch the product into the US market soon.

Aripiprazole tablets are part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Applications (ANDAs) of which it has 14 final approvals, including the current approval, two tentative approvals and 10 ANDAs under review with the US FDA.